Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06814522 · ClinicalTrials.gov registry record · Phase 1

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout

A Phase 1 study of Burnout and Burnout, Healthcare Workers, sponsored by University of California, San Diego.

Recruiting
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT06814522 is a Phase 1 study of Burnout and Burnout, Healthcare Workers that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 10 participants, below the 779-participant average among 13 other Burnout trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06814522, a Phase 1 study of Burnout and Burnout, Healthcare Workers, is actively recruiting participants, sponsored by University of California, San Diego.

RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms.

Interventions

  • DRUG Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate

Study Locations (1)

California

  • UC San Diego - San Diego

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-01-13
Est. Completion 2026-07
Phase Phase 1

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT06814522

The ClinicalTrials.gov registry entry for NCT06814522 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 779-participant average among 13 other Burnout trials with a reported enrollment target (99% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Burnout appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate is the first listed.

NCT06814522 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06814522 about?

NCT06814522 is a clinical study titled "Psilocybin-Assisted Therapy for Physician Well-Being and Burnout". Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms.

What is the current status of trial NCT06814522?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-01-13. Estimated completion is 2026-07.

What conditions does trial NCT06814522 study?

This clinical trial studies the following conditions: Burnout, Burnout, Healthcare Workers.

What interventions are being tested in trial NCT06814522?

The interventions under investigation include: Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (DRUG).

Who is sponsoring clinical trial NCT06814522?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06814522 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Burnout

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.